Mobile

A phase 3 trial studying how well lenvatinib works in treating patients with liver cancer who would not benefit from surgery compared against sorafenib. The trial is taking place worldwide, patients a...

Update Il y a 4 ans
Reference: EUCTR2012-002992-33

A phase 3 trial studying how well lenvatinib works in treating patients with liver cancer who would not benefit from surgery compared against sorafenib. The trial is taking place worldwide, patients and their physician will know if they are receiving lenvatinib or sorafenib

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

The primary objective of the study is to compare overall survival (OS) in subjects treated with lenvatinib versus sorafenib as a first-line treatment in subjects with unresectable heptocellular carcinoma (HCC)

Inclusion criteria

  • Unresectable Hepatocellular Carcinoma

Links